Actualités

Teladoc Health Inc (NYSE:TDOC) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. On May 1, Jefferies raised its price target Teladoc shares to $6 from $5.20 while keeping a Hold rating on the stock. Even so, the firm’s new price target remains below Teladoc’s current […]

It would be quite the feat for this struggling company.

Teladoc Health (NYSE:TDOC) is reporting flat sales over consecutive years, despite continued investment in its virtual care platform. Average revenue per user has been declining, pointing to weaker consumer monetization and softer engagement levels. Management has focused on broadening services, but this has not translated into stronger top line growth or higher earnings quality. The outlook for the next twelve months remains subdued, highlighting ongoing challenges for the...

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Teladoc currently trades at $6.81 per share and has shown little upside over the past six months, posting a small loss of 1.6%. The stock also fell short of the S&P 500’s 9.9% gain during that period.

Cathie Wood‘s ARK Invest joined Kalshi’s $1 billion Series F last week at a $22 billion valuation, slotting the prediction market behind only SpaceX and OpenAI in the ARK Venture Fund. Wood called prediction markets “a powerful new layer of financial infrastructure.” Kalshi will be hoping this prediction is more accurate than many of her previous ones. A Decade Of Big Calls That Did Not Land Morningstar analyst Amy Arnott labeled the ARK fund family the worst wealth destroyer of any U.S. fund gr

If you are trying to figure out whether Teladoc Health is attractively priced or not, the recent share moves give you plenty to think about. The stock last closed at US$6.66, with returns of 11.0% over the past week and 26.4% over the past month, while the year-to-date return is a 5.5% decline and the 1-year return is a 1.8% decline, alongside a 73.4% decline over 3 years and a 95.4% decline over 5 years. Recent coverage has focused on Teladoc Health's position in telehealth and digital care...

Teladoc Health posts a y/y narrower Q1 loss and beats revenue estimates as international growth and cost cuts offset BetterHelp weakness and subscription declines.

Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 7.1% in the afternoon session after the stock's positive momentum continued as it raised its price target on the stock to $9.00 from $8.25 and maintained a Buy rating.

Teladoc Health (NYSE:TDOC) reported first-quarter 2026 results that Chief Executive Officer Chuck Divita said came in above the midpoint of the company’s guidance for both revenue and Adjusted EBITDA, driven by solid performance in Integrated Care and continued progress scaling BetterHelp’s insuranc

Digital medical services platform Teladoc Health (NYSE:TDOC) reported Q1 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 2.5% year on year to $613.8 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $611.5 million was less impressive, coming in 2% below expectations. Its GAAP loss of $0.36 per share was 3.6% below analysts’ consensus estimates.

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

Teladoc Health, Inc. recently reported first-quarter 2026 results, with sales of US$613.85 million versus US$629.37 million a year earlier and a net loss of US$63.84 million compared with US$93.01 million. While revenue slipped, the reduced net loss and lower loss per share highlight Teladoc’s efforts to tighten operations and move closer to breakeven. We’ll now examine how Teladoc’s lower quarterly net loss, despite softer revenue, may influence its existing investment narrative and...

Moby summary of Teladoc Health, Inc.'s Q1 2026 earnings call

Teladoc Health Inc (TDOC) reports robust revenue growth and strategic advancements in AI and insurance, despite challenges in cash flow and business model shifts.

While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teladoc (TDOC) delivered earnings and revenue surprises of -13.82% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Digital medical services platform Teladoc Health (NYSE:TDOC) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.5% year on year to $613.8 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $611.5 million was less impressive, coming in 2% below expectations. Its GAAP loss of $0.36 per share was 4.7% below analysts’ consensus estimates.